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Aquaporins in cancer development: opportunities for 
bioinorganic chemistry to contribute novel chemical probes and 
therapeutic agents   
Brech Aikman,a Andreia de Almeida, a Samuel M. Meier-Menchesa,b and Angela Casini †a 
Aquaporins (AQPs) are membrane proteins allowing permeation of water, glycerol & hydrogen peroxide across 
biomembranes, and playing an important role in water homeostasis in different organs, exocrine gland secretion, urine 
concentration, skin moisturization, fat metabolism and neural signal transduction. Notably, a large number of studies 
showed that AQPs are closely associated with cancer biological functions and expressed in more than 20 human cancer cell 
types. Furthermore, AQPs expression is positively correlated with tumour types, grades, proliferation, migration, 
angiogenesis, as well as tumour-associated oedema, rendering these membrane channels attractive as both diagnostic and 
therapeutic targets in cancer. Recent developments in the field of AQPs modulation have identified coordination metal-
based complexes as potent and selective inhibitors of aquaglyceroporins, opening new avenues in the application of 
inorganic compounds in medicine and chemical biology. The present review is aimed at providing an overview of AQPs 
structure and function, mainly in relation to cancer. In this context, the exploration of coordination metal compounds as 
possible inhibitors of aquaporins may open the way to novel chemical approaches to study AQPs roles in tumour growth 
and potentially to new drug families. Thus, we describe recent results in the field and reflect upon the potential of inorganic 
ĐheŵistƌǇ iŶ pƌoǀidiŶg ĐoŵpouŶds to ŵodulate the aĐtiǀitǇ of ͞elusiǀe͟ membrane targets as the aquaporins. 
 
Introduction 
The identification of aquaporins (AQPs), highly conserved membrane 
protein channels that are permeated by water, revised the general 
view on water passage across biomembranes as being solely the 
result of passive diffusion across the lipid bilayer.1,2 The last decade 
contributed greatly to the understanding of the diverse roles of AQPs 
in health and disease. Particularly, the ability of AQPs to permeate 
not only water but also other small molecules or solutes, enables 
them to regulate several cell functions, which include osmotic water 
movement in cell volume regulation, energy metabolism, migration, 
adhesion and proliferation.3–6 Presently, thirteen mammalian AQP 
isoforms (AQP0-12) have been identified, ubiquitously distributed 
throughout the body. Based on structural and functional 
characteristics, these channel proteins are divided into two main 
groups: orthodox aquaporins strictly involved in water permeability 
(APQ0-2, AQP4, AQP5, AQP6 and AQP8) and aquaglyceroporins, 
facilitating transport of small uncharged solutes such as glycerol and 
urea, additionally to water (AQP3, AQP7, AQP9, and AQP10).7 
Peroxiporins are a further subclass of AQPs permeable to hydrogen 
peroxide, and comprise both orthodox aquaporins (AQP1, AQP8) and 
aquaglyceroporins (AQP3 and AQP9). Finally, due to their subcellular 
localization, AQP11 and AQP12 are classified as S-aquaporins.8,9 The 
nature of selective permeability for the latter is still uncertain and 
they show less sequence similarity to the other isoforms. However,  
 
 
 
 
 
 
 
there are indications of AQP11 facilitating water and glycerol 
transport.10,11  
Pathophysiological conditions of numerous human disorders 
have been correlated with altered aquaporin function as a result of 
dys-, up- or down-regulated AQPs expression (Fig. 1).12 Nephrogenic 
diabetes insipidus and Sjörgens syndrome are just two examples of 
disorders linked to impaired water permeability of AQPs.13 The 
dǇsfuŶĐtioŶ of aƋuaglǇĐeƌopoƌiŶs͛ aďilitǇ to permeate glycerol, as 
well as their abnormal expression in certain tissues, have 
consequences for cell proliferation, adipocyte metabolism and 
epidermal water retention. Thus, aquaglyceroporins seem to play a 
role in metabolic disorders such as obesity, diabetes and skin 
diseases, e.g. atopic dermatitis.14,15 Interestingly, studies report 
isoforms of both orthodox aquaporins and aquaglyceroporin linked 
to different types of cancer, often showing a strong correlation 
between the level of AQP expression and the tumour grade.5,16–18 
Notably, parasite aquaglyceroporins are also relevant to certain 
human diseases, such as malaria.19  
  
Fig. 1 Human diseases related to an abnormal function or altered expression of different 
AQPs isoforms. 
Since aquaporins are involved in a variety of important physiological 
and pathophysiological processes, they have gained increasing 
attention as promising targets for therapeutic intervention. 
However, discovering selective AQPs modulators (inhibitors) proved 
to be challenging. Such inhibitors would not only be useful as novel 
therapeutic agents but also as chemical probes to validate AQPs 
function in biological systems, to be used in parallel to genetic 
approaches (e.g. knockout animal models). After presenting a 
general overview on AQP structure and expression in both healthy 
and tumour tissue, this perspective will focus on the role of AQPs in 
tumorigenesis and tumour metabolism and summarize the state-of-
the-art literature on the most promising AQP-targeted metal-based 
inhibitors highlighting their possible uses in medicine and cancer 
pathophysiology.  
1. Aquaporin structure  
Aquaporins are homo-tetrameric complexes in the cell membrane, 
with each monomer of ~ 30 kDa containing six transmembrane -
helices connected by five loops, two half helices and both N- and C-
termini located on the cytoplasmic side of the membrane.20,21 Two 
of the loops are located intracellularly while three are extracellular 
domains.20 Each AQP monomer in the membrane creates a single 
narrow hourglass-shaped pore spanning the lipid bilayer (Fig. 2).22 
Specific features of this channel are essential to the remarkable 
selective nature of AQPs for permeation of water and other small 
solutes, namely two highly conserved constriction sites acting as 
selectivity filters.4,20 The constriction site located near the 
extracellular entrance is known as the aromatic/arginine selectivity 
filter (ar/R SF) (Fig. 2) and the diameter of this filter determines 
whether small polar solutes may permeate the pore in addition to 
ǁateƌ. IŶ oƌthodoǆ aƋuapoƌiŶs the poƌe͛s diaŵeteƌ at the ar/R SF is 
ca. 3 Å, preventing permeation of molecules bigger than water (2.8 
Å).20 The size of the pore is larger in aquaglyceroporins, reaching up 
to ~3.4 Å in diameter to allow for example glycerol permeation.21,23,24 
Although the arginine in this constriction site is fully conserved in all 
mammalian AQPs isoforms, the composition of the remaining amino 
acids creating the ar/R SF might vary depending on the permeability 
for water or glycerol. Orthodox aquaporins have an ar/R SF formed 
by four residues, while aquaglyceroporins have an ar/R SF formed by 
only three residues, which most likely accounts for the different pore 
sizes and selectivity.21 
The second selectivity filter is composed of two conserved 
asparagine-proline-alanine (NPA) motifs, located in the centre of the 
channel where the positive N-terminal ends of the two half helices 
meet. The formed helix dipole moment adds to these positive ends, 
creating an electrostatic barrier that prevents the passage of 
positively charged ions through the pore.25 Particularly the Asn side 
chain amide position appears to be structurally critical to this 
functionality, whilst the amide nitrogens aid in directing water or 
solute molecules by acting as hydrogen bond donors.26 Molecular 
dynamics (MD) simulations, electron microscopy and X-ray 
crystallographic structures of AQPs revealed water molecules 
passing through the channel in a single file, orienting themselves 
along the local electrical field.23,27 Unlike the previously mentioned 
structural difference found between AQPs and aquaglyceroporins in 
the ar/R SF, the NPA region is conserved in most human AQP 
isoforms, with the exception of AQP7 (NAA-NPS), AQP11 (NPC-NPA) 
and AQP12 (NPT-NPA). However, all AQPs preserve the Asn residue, 
thus emphasizing its importance.  
 
Fig. 2 Homology model of human AQP3. (A) Extracellular top view of the tetrameric form 
of hAQP3. (B) Side view of the tetrameric form of hAQP3, with the conserved 
aromatic/Arginine selectivity filter (ar/R SF) and the NPA motifs. 
 2. Aquaporins in normal and tumour physiology 
Numerous studies observed a correlation between AQP expression 
levels in cancer cells and cancer malignancy.5,16,28 However, this 
observation does not imply that only one type of AQP relates to a 
specific cancer. In fact, multiple AQP isoforms were reportedly 
involved in tumours at different stages.16,29 Interestingly, some 
tumours also showed up-regulated expression of AQPs isoforms 
which are usually not found in the tissue of origin. Table 1 provides 
an overview of the presence of different AQP isoforms in various 
human cancer types (studied in cells or tissue samples) and possible 
related functions. The involvement of aquaporins in tumours can be 
partially dependent on the nature of their substrate permeability, as 
will be explored further in the next sections. Thus, here we will 
summarize some of the studies that best describe the function of 
different AQPs isoforms in cancer development. 
2.1 Water permeation 
The presence of AQPs in human tissues facilitates water permeation 
across the membrane, allowing fast cellular responses to changes in 
the osmotic gradient. Therefore, AQPs are abundantly present in 
tissues involved in maintaining water-based homeostasis, with a 
need for rapid fluid turnover such as the kidneys (AQP1, AQP2, AQP3, 
AQP4),30 the airways (AQP1, AQP3, AQP5)30,31 and the central and 
peripheral nerve system (AQP1, AQP4, AQP9).32,33 Notably, the 
ability of AQPs to transport water was proven to be involved in 
multiple aspects of tumour malignancy, e.g. enhanced cell 
migration,34 affecting tumour invasion35 as well as oedema 
formation,32,36 as detailed below. 
 
 
Table 1. Expression of AQP isoforms in different human tumours and cancer cell lines. 
AQP isoform Tumour and sample type Function in tumour 
 Tissue Tissue & Cells Cells  
AQP0    Unknown 
AQP1 Brain32,37, Breast38, Colorectal39, 
Cervical40, Laryngeal41, Lung42, 
Ovarian43, Renal44, Mesothelium45 
Bone46, Breast47*, 
Colorectal48, Lung35  
 Grade, prognosis, proliferation, angiogenesis, 
necrosis, migration, invasion and metastasis. 
 
AQP2    Unknown 
AQP3 Cervical40, Bladder49, Colorectal39, 
Liver50, Lung18,42, Oesophageal51, 
Pancreas29, Renal52, Uterus53 
Colorectal48, Head and 
Neck54, Stomach55,56, 
Prostrate57 
Breast58, Skin59  Grade, prognosis, angiogenesis, invasion, 
migration and energy metabolism. 
 
AQP4 Brain32,36, Cervical40 Thyroid60, Lung35  Grade, migration, tumour-associated oedema, 
adhesion, invasion and apoptosis. 
AQP5 Breast61, Cervical40,62, Colorectal39, 
Liver50, Lung63, Oesophageal51, 
Ovarian64, Pancreas29 
Breast65, Colorectal48,66, 
Myeloblast67, Prostate68, 
Stomach69,70, Tongue54 
Lung33, Ovarian72 
 
 
Prognosis, proliferation, invasion, migration and 
drug resistance. 
 
AQP6 Ovarian73   Grade 
AQP7 Thyroid74, Uterus53   Unknown 
AQP8 Brain75, Cervical40,76, Ovarian73   Myeloblast77 Migration, invasion, metastasis and anti-
apoptosis, grade, proliferation. 
AQP9 Brain78, Liver79, Ovarian80, Uterus53 Liver81  Grade, drug resistance, and energy metabolism. 
AQP10    Unknown  
AQP11   Lung82 Prognostic 
AQP12    Unknown  
*Primary cells 
 
 
 
 
 
 Migration of tumour cells 
The ability of tumour cells to migrate enables tissue invasion and 
metastasis, which are both associated with a poor prognosis.83 AQPs 
1, 4 and 5 are the main AQP isoforms shown to be involved in general 
cell migration. Under normal physiological circumstances, AQP1 
expression is polarized on the leading edge of cell protrusions in 
migrating cells, which is hypothesized to enhance the process of cell 
movement.34 The increased water permeability combined with actin 
cleavage and ion uptake at the tip of the lamellipodia create local 
osmotic gradients, which drive water influx and ultimately enable 
lamellipodia extension and cell migration.34,84 It was suggested that 
AQPs facilitate the rapid changes in cell shape that take place as a 
migrating cell squeezes through the extracellular matrix. Such cell 
 volume changes are likely to require rapid water flow in and out of 
the cell, thus justifying the presence of AQPs water channels.34 In 
tumour cells, overexpression of AQPs could, therefore, enhance their 
ability for tissue invasion and metastasis. In line with this hypothesis, 
cancer cell lines over-expressing AQP1 demonstrate an increased 
ability to extravasate across blood vessels and to invade local tissue 
in vitro and in vivo.85 Similarly, over-expression of AQP1 in pulmonary 
adenocarcinoma tissue samples instigated a stronger capacity of 
cancer cell migration, invasion and metastasis.42 Several in vitro and 
in vivo assays confirmed a decreased ability of cells to migrate when 
the expression of AQPs is impaired.86,87 
A similar effect was observed in the expression of AQP4 in 
astrocytes. In normal brain tissue, AQP4 is primarily localized around 
tight junctions of astrocytic end-feet at the cerebral microvessels, 
facing the blood-brain barrier, which is formed by endothelial cells. 
Thus, AQP4 facilitates the movement of water between blood and 
the brain and between the brain and cerebrospinal fluid 
compartments.88 However, in brain tumours and especially diffuse 
astrocytomas, AQP4 expression is greatly upregulated and 
intracellularly redistributed across the plasma membrane of the 
cancerous astrocytes, showing a completely different morphology 
from healthy cells.32 This change in phenotype also facilitates 
astroglial cell migration. In the comparison between wild-type and 
AQP4-null astrocytes, the latter displayed slow migration.32,36 
Interestingly, detecting the expression levels of AQP4 to distinguish 
benign from malign thyroid nodules was the claim of a recent 
patent.89 The invention is based on the discovery that AQP4 
immunostaining of suspected follicular neoplasm can facilitate the 
distinction of benign from malign oncocytic lesions, and it seems 
useful in deciding which thyroid nodules should be dissected or 
removed in thyroid surgery. 89 
Concerning AQP5, its upregulation was linked in several tumours 
to enhanced migration and invasive phenotypes.65,90 In fact, 
overexpression of this isoform has been correlated with lymph node 
metastases in ovarian64, prostate68, colon39, cervical40, lung63 and 
oesophageal51 cancers. In lung cancer cells in vitro, AQP5 
overexpression was associated with increased cell migration, while 
AQP5 knockdown led to decrease in cell migration and invasion 
properties.71  A similar effect was observed in the migration of gastric 
carcinoma70 cells and invasion of breast cancer cells65. Another in 
vitro study, using human glioma cells showed that increased AQP5 
mRNA expression was positively correlated with proliferation rates 
and silencing inhibited cell proliferation, reduced migration and 
promoted cell apoptosis.91 Recently, the role of AQP5 in 
hepatocellular carcinoma metastasis was also evaluated.92 The 
authors showed that AQP5 was highly expressed in hepatocellular 
carcinoma cell lines aŶd its doǁŶƌegulatioŶ iŶhiďited the Đells͛ 
capacity of invasion and metastasis, both in vitro and in vivo. 
Tumour oedema 
Upregulation of AQPs as water channels may also contribute to 
oedema formation and patients with tumour oedema in the brain 
display an increased morbidity and mortality rate.32 For example, 
AQP1 was found upregulated in glioblastomas, enhancing the water 
permeability in perivascular areas like the blood-brain barrier.37,93 
Based on these studies, AQP1 has the potential to be applied as a 
survival prognosticator in glioblastoma.94 Over-expression of AQP4 
was also associated with tumour oedema in the brain.36 However, 
due to the upregulation of AQP4 in the peritumoral area rather than 
the tumour core, its involvement in migration might be even more 
relevant.95 Subsequent experiments showed that AQP4 deletion in 
mice increased oedema around implanted melanoma in the brain, 
suggesting that the increased AQP4 expression by reactive astrocytes 
in and around the tumour facilitate elimination of brain oedema 
fluid.96 
2.2. Glycerol transport 
Concerning aquaglyceroporins (AQPs 3, 7, 9, 10 and 11)  and their 
roles in physiology, as expected their expression is particularly high 
in tissues involved in glycerol metabolism such as adipocytes and 
liver, and thus, influences metabolic pathways.97,98 Circulating 
glycerol derives from fat lipolysis, glycerol absorbance from the 
 strointestinal tract or re-absorbance in the proximal tubules in the 
kidneys.99 Glycerol is an important intermediate in gluconeogenesis, 
lipid metabolism and in an electron shuttle system into 
mitochondria. The latter carries reducing equivalents from the 
cytosol to mitochondria for oxidative phosphorylation.100 Depending 
on the cellular energy status, metabolism can take place in the outer 
mitochondrial membrane.  
In the body, glycerol is stored in adipose tissue in the form of 
triacylglycerol (TAG), which may derive from glycolysis. The TAG 
precursors are CoA-activated fatty acids and glycerol-3-phosphate 
(G-3-P), produced either from the reduction of dihydroxyacetone 
phosphate (DHAP) or the phosphorylation of glycerol.101 Adipose 
tissue or muscles do not express glycerol kinase (GK), the enzyme 
required for glycerol phosphorylation, which is why they acquire G-
3-P from glycolysis. AQP7 is the primary glycerol transporter in 
adipose tissue and abundantly expressed in the plasma membrane 
of adipocytes (Fig. 3).102 However, recently, AQP11 has also been 
identified in human adipocytes in the vicinity of lipid droplets and to 
be able to permeate glycerol.10  
Under fasting conditions, glycerol released by adipose tissue 
upon lipolysis is taken up by the liver, most likely via AQP9,79 and 
used as a non-carbohydrate precursor to induce gluconeogenesis in 
hepatocytes.101 Thus, AQP7 seems to facilitate glycerol efflux from 
adipose tissue, leading to glycerol influx into hepatocytes via 
AQP9.102,103 
Similarly to the orthodox aquaporins, aquaglyceroporins are also 
involved in osmoregulation. In fact, glycerol is one of the main 
osmoprotective solutes in mammalian cells.100 In response to 
external gradients, cells can react by altering intracellular levels of 
glycerol whilst reducing or increasing membrane permeability. Like 
water, glycerol can cross the lipid bilayer via passive diffusion. 
However, this process is relatively slow and the presence of 
aquaglyceroporins highly increases glycerol permeability, turning 
glycerol permeation into a faster and more energy efficient process. 
In the skin, AQP3 is the most abundantly expressed isoform, in 
particular in keratinocytes residing in the basolateral layer of the 
epidermis.104  Under physiological conditions, water and glycerol are 
essential in preserving skin moisture. Glycerol acts as a humectant to 
prevent water evaporation, thus upholding the barrier function of 
the skin.105 In mice, deletion of AQP3 was shown to impair this barrier 
function by reducing elasticity and hydration, as well as showing 
delayed wound healing and reduced cell proliferation in the stratum 
corneum.106  
Fig. 3 Aquaglyceroporins and glycerol metabolism in liver and adipose tissue. 
Abbreviations: G-3-P = glycerol 3-phosphate, DHAP = dehydroxyacetone phosphate, TCA 
= tricarboxylic acid, FFA = free fatty acid, TAG = triacylglycerol, MAG = monoacylglycerol. 
Glycerol in cancer cell proliferation 
Overall, the experimental evidence describing increased 
aquaglyceroporin expression in tumours (Table 1) led to the 
hypothesis that glycerol contributes to tumour growth and cancer 
cells proliferation in two possible ways: i) as a building block in 
phospholipid synthesis, and/or ii) as an intermediate or regulator of 
ATP production.97 Since both pathways are essential to fast 
proliferating cells, such as cancerous ones, AQPs inhibition is 
predicted to reduce both tumour cell proliferation and migration. 
Below we will summarize the studies that corroborate these 
hypotheses on the interplay between glycerol and cancer. 
Out of the four human aquaglyceroporin isoforms, AQP3 is the 
most studied also in relation to cancer. This isoform is widely 
distributed throughout the body in epithelial cells.105,107 A recent 
study by our group, showed that AQP3 inhibition reduced cell 
proliferation as a function of the AQP3 expression levels in different 
cell lines, including cancer cells. 108 Furthermore, it was found that 
AQP3 silencing induced downregulation of several lipid synthases in 
gastric cancer cells in vitro.109 Thus, it was postulated that lipid 
synthesis impairment by AQP3 knockdown is not only the 
consequence of glycerol uptake decrement but also related to lipid 
synthesis system inhibition. The PI3K (phosphatidylinositol-4,5-
 bisphosphate 3-kinase) /Akt (protein kinase B) signalling pathway, 
which was involved in the impaired lipid and ATP production, was 
also inhibited after AQP3 knockdown.109  
 As cancer cells divide at higher rates, they require more lipids for 
membrane synthesis, and more energy to sustain the vigorous 
proliferation and the malignant behaviour. In fact, phospholipids are 
used to form the various plasma membranes, but can also be 
catabolized to generate ATP ďǇ β-oxidation.110,111 As previously 
mentioned, glycerol can be metabolized to be the backbone of 
triglyceride (TAG), and TAG is important in maintaining cell 
proliferation and survival.  Specifically, tumour cells can convert TAG 
into free fatty acid (FFA) by lipolytic processes (Fig. 4). Fatty acid 
oxidation (FAO) is used to generate ATP to support the cancer 
development.112 Thus, inhibition of lipid synthesis, via 
aquaglyceroporins inhibition or down-regulation, may result in 
material and energy supply defects.  
The second main hypothesis for the role of AQP3 in tumour cell 
migration and proliferation relates to the fact that its over-
expression provides the cell with higher glycerol permeability leading 
to higher ATP content,113 required for a greater demand for 
biosynthesis. This idea of a direct correlation between glycerol and 
ATP production was developed in 2008, when Hara-Chikuma and 
Verkman observed a remarkable resistance to skin tumorigenesis in 
AQP3-deficient mice.59 Their data suggested that glycerol 
permeability via AQP3 is required for epidermal cell proliferation and 
tumorigenesis, as the cellular glycerol levels were positively 
correlated with cellular ATP content.59 In detail, a reduction of 
glycerol in epidermal cells, its metabolite G-3-P, and ATP were 
observed in AQP3-deficiency without impairment of mitochondrial 
function.59 Glycerol supplementation corrected the reduced 
proliferation and ATP content under AQP3 deficiency. Thus, it was 
suggested that glycerol could be a key regulator of cellular ATP, 
which could justify the overexpression of AQP3 in some cancers.   
However, this hypothesis needs some careful reflection on the 
biochemical pathways possibly linking glycerol to ATP synthesis, 
particularly in relation to cancer cell metabolism. In general, tumours 
display a deregulated metabolism to meet the high demand for 
nutrients used to support cell proliferation and survival, while 
maintaining a balanced redox status.114 Thus, in cancer, glucose and 
glutamine are often the main energy sources.115,116 In the early 20s, 
Warburg theorized that impaired mitochondrial respiration would 
drive tumorigenesis and cause an increased consumption of glucose, 
reflected in high lactate production, i.e. aerobic fermentation, 
named the Warburg effect.117 However, current research challenges 
this interpretation postulating that tumours retain their capacity to 
perform oxidative phosphorylation, even within the hypoxic 
environment, and metabolic changes are rather an effect of various 
malignant cellular transformations than a cause of 
tumorigenesis.114,118 
Proliferating cancer cells have an increased need for precursors 
and intermediates for biosynthesis and reducing equivalents, which 
the catabolism of glucose and glutamine can provide.118 Oxidation of 
carbon skeletons, produced from glucose, allows the cells to capture 
the electrons in the form of reduced nicotinamide adenine 
dinucleotide (NADH), which are then introduced into the 
mitochondrial electron transport chain via the malate-aspartate 
shuttle. This process contributes to cellular respiration and ATP 
generation.118 Proliferating tumour cells seem to prefer converting 
excess pyruvate into lactate, which contributes to maintaining the 
cytoplasmic level of the NAD+/NADH ratio to promote a continued 
glucose metabolism.118,119 
In this context, tumours overexpressing aquaglyceroporins are 
thought to use glycerol as an intermediate for pyruvate through the 
glycerol 3-phosphate shuttle (G-3-P shuttle) leading to ATP 
production (Fig. 4). The G-3-P shuttle is a complex process used to 
transfer electrons from cytosolic NADH to the mitochondrial electron 
transport chain (Fig. 4).120 In this shuttle, the enzyme called 
cytoplasmic glycerol-3-phosphate dehydrogenase 1 (cGPDH) 
converts dihydroxyacetone phosphate to G-3-P by oxidizing one 
molecule of NADH to NAD+, whilst the mitochondrial glycerol-3-
phosphate dehydrogenase (mGPDH) converts G-3-P to DHAP by 
reducing flavine adenine dinucleotide (FAD+)120 This system 
regenerates cytosolic oxidized nicotinamide adenine dinucleotide 
(NAD+) and supports oxidative phosphorylation in mitochondria, thus 
production of adenosine triphosphate (ATP). In humans, the G-3-P 
shuttle functions mainly in the brain and skeletal muscle.101  
In proliferating cells, glycerol phosphorylation is catalysed by 
Glycerol Kinase (GK), converting glycerol to G-3-P.100 The G-3-P can 
either be utilized in the biosynthesis of phospholipids as an 
important structural component of cellular membranes or enter the 
glycolytic pathway, when converted to DHAP by mGPDH.100,101,121 
However, the latter is less likely to occur, as proliferating cells 
interconvert DHAP to G-3-P in order to re-oxidize cytosolic NADH 
generated from glycolysis, transferring reducing equivalents into the 
electron transport chain. The enzyme mGPDH shows an increased 
activity in prostate cancer cells, melanoma and breast cancer, 
 thought to uphold glycolysis and facilitating the oxidation of 
NADH.122  
Fig. 4 Possible model of aquaglyceroporin involvement in glycerol metabolism of 
proliferating tumour cells. Abbreviations: ATP = adenine triphosphate, DHAP = 
dehydroxyacetone phosphate, FAD+ = flavine adenine dinucleotide, FADH2 = 
hydroquinone form of flavine adenine dinucleotide, FFA = free fatty acids, cGPDH and 
mGDPH = cytosolic and mitochondrial, respectively, glycerol-3-phosphate 
dehydrogenase, G1Pa = glucose 1-phosphate-adenyltransferase, G-3-P = glycerol 3-
phosphate, GK = glycerol kinase, TCA = tricarboxylic acid, NAD+ = oxidized nicotinamide 
adenine nucleotide, NADH = reduced nicotinamide adenine nucleotide. 
It is important to recognize that cancer cell metabolism is 
continuously adapting and reprogramming to optimize the use of 
available nutrients. Overall, although glycerol is more likely to 
contribute to tumour cell growth as a precursor for phospholipids, its 
interplay in the generation of ATP cannot be ruled out, and this 
aspect would warrant further investigation.  
Despite AQP3 being the most studied isoform in relation to 
cancer, all other aquaglyceroporins have been shown to be 
expressed in cancer tissue, with an established correlation to several 
types of cancers (Table 1).  
For example, immunostaining of AQP7 in epithelial ovarian 
cancer showed expression in the plasma membranes of benign 
tumour cells, while being located in the nuclear membrane of 
borderline and malignant cells.80 Interestingly, despite the selective 
nuclear staining in malignant tumour tissue, western blot analysis of 
protein levels showed that AQP7 is significantly higher in malignant 
and borderline tumour than in benign tumour and normal ovarian 
tissue. This indicates that translocation and expression of this 
isoform may be crucial for ovarian carcinogenesis. 
 AQP9 has been shown to be in human glioblastoma, most glioma 
cells showing high AQP9 protein expression on the cell surface.123 
Other authors have shown that AQP9 mRNA is present in specific 
subpopulations of glioma cells and leukocytes infiltrating the tumour 
tissue.124 Moreover, work by Fossdal et al. revealed that AQP9 mRNA 
and protein expression is increased in glioblastoma stem cells.125 
Expression of this isoform in glioblastoma may indicate a role in 
glioma-associated lactic acidosis, by facilitating glycerol and lactate 
excretion, and/or being involved in the energy metabolism of glioma 
cells. This example highlights the crucial role of AQPs not only in 
glycerol uptake but also in regulating its efflux (Fig. 4). In epithelial 
ovarian cancer, AQP9 was shown to be localized in the basolateral 
membranes of both benign and borderline tumour cells, while it was 
widely distributed throughout membranes of malignant cells.80 
Moreover, protein expression analysis by western blot revealed that 
there is a significant difference between tumour types as follows: 
ovarian malignant > borderline > benign/normal tissue. Interestingly, 
AQP9 was shown to be higher expressed in mucous than serous 
ovarian tumours and also correlated with tumour grade: higher 
expression in undifferentiated (grade 3) than well differentiated 
(grade 1/2) tumours.78,80 Therefore, increased AQP9 expression may 
be related to poor prognosis, highlighting once more the importance 
of understanding the role of aquaglyceroporins and glycerol in 
carcinogenesis.   
Interestingly, AQP9 was shown to be down-regulated in 
hepatocellular carcinoma.81 Moreover, its overexpression 
suppressed cell invasion, both in vitro and xenograft tumour growth, 
as well as hepatoma cell invasion by inhibiting epithelial-to-
mesenchymal transition. This fact clearly shows that the role of 
aquaglyceroporins in cancer development may differ according to 
specific tissue types aŶd the tissue͛s ƌeƋuiƌeŵeŶt of eitheƌ glǇĐeƌol 
uptake or efflux. 
Little is known about the role and expression of AQP10 and 11 in 
cancer. One study, that used microarray data to investigate 
prognostic values of AQP mRNA expression in human ovarian cancer, 
showed that AQP3, 10 and 11 are correlated with improved overall 
survival in ovarian cancer patients.126 However, nothing is known 
about the protein expression of AQP10 and 11 in cancer cells or 
tissues. 
 Finally, while the correlation of aquaglyceroporins with several 
types of cancers is established (Table 1), as anticipated in the 
previous examples, the need of tumours for glycerol could be 
dependent of their type and stage of differentiation. Thus, 
metastatic and non-metastatic cancers may also have different 
aquaglyceroporin expression, even within the same tissue origin. For 
example, using high-throughput technology with microarray 
datasets, it was shown that, in melanoma, the transition to an 
increased malignant phenotype was correlated to a reduced 
expression of AQP3 compared to normal skin and benign nevi. 127 
Thus, the requirement for glycerol might decrease, as the focus shifts 
from tumour proliferation to migration.  
The possible role of AQP3 downregulation as an indicator for the 
invasive character was also observed in prostate tumours.127 These 
findings are supported by Jain. et al., who examined consumption 
and release of 219 metabolites in the medium of the 60 cell lines of 
the NCI-60 screen.115 Their results suggest increased consumption of 
glycerol in some non-metastatic over metastatic cancer cell lines. 
Overall, it is important to note that glycerol requirements may 
vary with the specific tissue of origin, malignancy, differentiation and 
metastatic properties, making aquaporins very challenging to study. 
Furthermore, due to AQPs bi-directioŶalitǇ of peƌŵeatioŶ, tuŵouƌs͛ 
need to control glycerol uptake or efflux may lead to decreased 
expression of particular isoforms.  
2.3 Hydrogen peroxide transport 
Similarly to water, H2O2 was originally thought to freely cross the cell 
membrane by means of passive diffusion. However, experimental 
studies suggested rapid diffusion through the lipid bilayer was likely 
facilitated by membrane protein like AQPs.128–130 Currently, there is 
evidence for H2O2 permeation by AQP3,131 AQP8132 and AQP9133, 
while hydrogen peroxide permeation of AQP1 is still 
controversial.130,131 Since isoforms from both orthodox AQPs and 
aquaglyceroporins have hydrogen peroxide as a substrate, they are 
also referred to as peroxiporins. AQP3 and AQP9 can both be found 
in the plasma membrane, whereas AQP8, in addition to its plasma 
membrane localization, is also present in the inner membrane of 
mitochondria, which are a major source of reactive oxygen species 
(ROS) in animal and plants.134 For example, Marchissio et al. 
examined whether knockdown of mitochondrial AQP8 (mtAQP8) in 
human hepatoma cells using siRNA had an effect on mitochondrial 
H2O2 efflux. 135 The authors found that, compared to wild-type 
mitochondria, isolated mtAQP8 knockdown mitochondria had a 
lower H2O2 efflux ability, while the cells suffered from reduced 
viability. Hydrogen peroxide is part of the ROS that comprise 
superoxide, superoxide radicals and hydroxyl radicals. In healthy 
cells, ROS play a significant role in maintaining homeostasis, where 
intra- and extracellular concentrations of ROS are controlled using 
scavenging systems to balance ROS generation and elimination.136 
ROS are generated as a by-product of aerobic metabolism, with 
nicotinamide adenine dinucleotide phosphate oxidases (NOX) and 
the mitochondrial electron transport chain (mETC) as the main 
sources.137 Scavenging enzymes and antioxidant agents that limit 
ROS accumulation are superoxide dismutase (SODs), catalase, 
glutathione peroxidases, the thioredoxin system, heme-oxygenase 
and nicotinamide adenine dinucleotide phosphate (NADPH)/ 
nicotinamide adenine dinucleotide (NADP+).137,138 Depending on 
their concentration, ROS are involved in physiological or pathological 
changes and can activate signalling pathways to stimulate cell 
proliferation, differentiation, migration, apoptosis, adaption to 
hypoxia, immune function, and other processes.139 Alterations in 
cells͛ ability to transport ROS can, therefore, have a profound effect 
on their viability.  
Increased ROS levels, particularly hydrogen peroxide, are found 
in pathological conditions such as cancer.137,140,141 Specifically, 
hydrogen peroxide plays a role in (mitochondrial) NOX and ERK 
(extracellular-regulated kinase)-PI3/Akt. Both are activated by 
receptor tyrosine kinase (RTK) mediated cell signalling, and involved 
in cell survival, protein synthesis, proliferation and mTORC2 induced 
cell migration (Fig. 5).142 
 
 
 Fig. 5 Possible pathways of the interaction of AQP-permeated hydrogen peroxide in 
cancer cells. Abbreviations: Akt = protein kinase B, AQPs= peroxiporins, ERK = 
extracellular-regulated kinase, mTORC1 = mammalian target of rapamycin complex 1, 
mTORC2 = mammalian target of rapamycin complex 2, NF-κB = ŶuĐleaƌ faĐtoƌ kappa-
light-chain-enhancer of activated B cells, NOX = nicotinamide adenine dinucleotide 
phosphate oxidases, PI3K = phosphatidylinositol-4,5-bisphosphate 3-kinase, PIP2 = 
Phosphatidylinositol (4,5)-bisphosphate, PIP3 = Phosphatidylinositol (3,4,5)-
trisphosphate, PTEN = phosphatase and tensin homolog, RTK = receptor tyrosine kinase, 
SOD3 = superoxide dismutase 3.  
Interestingly, several authors have previously reported an 
association between peroxiporins and ERK, NOX, mTOR or PI3K/Akt, 
both in healthy143 as cancerous cells144,145. Involvement of AQP3 in 
the ERK pathways, for example, was demonstrated in vitro using 
human epidermal keratinocytes, where inhibition of ERK 
phosphorylation via ARNT (aryl hydrocarbon receptor nuclear 
translocator) activation led to both a downregulated expression of 
AQP3 and inhibited cell proliferation.143 The correlation between the 
peroxiporins and these pathways, linked to their ability to facilitate 
H2O2 transport, was not uncovered until recently. Hara-Chikuma 
et al. unexpectedly found that AQP3 was expressed not only by 
keratinocytes but also by skin-infiltrating T-cells and regulates their 
trafficking in cutaneous immune reactions.146 Specifically, it was 
demonstrated the necessity of AQP3 mediated H2O2 permeation in 
chemokine-dependent T-lymphocyte migration in mice, where 
knocked-down expression of AQP3 proved to impair movement of 
the cells during immune response.146 According to the obtained 
results, hydrogen peroxide is suspected to be involved in a signalling 
cascade resulting in the actin polymerization needed for cell 
movement, showing that cell migration may be at least partially 
dependent on H2O2. Recently, AQP3 has been shown to mediate 
hydrogen peroxide-dependent responses to environmental stress in 
colonic epithelia.147 Thus, the increased membrane permeability to 
H2O2 in AQP3-expressing colonic endothelial cell allowed them to 
respond to external H2O2 at concentrations relevant for cellular 
signalling processes (1–ϭϬϬ μMͿ, suĐh as ŵigƌatioŶ aŶd pathogeŶ 
recognition.147 
Modulated expression of AQPs in cancer cells can, therefore, be 
related not only to their ability to transport water or glycerol, but 
also H2O2. Hara-Chikuma et al. demonstrated that AQP3 permeated 
hydrogen peroxide is necessary for keratinocyte migration and 
proliferation, suggesting this to be the same processes which have 
been implicated in cutaneous wound healing and tumorigenesis.148 
It is most likely that the elevated concentrations of intracellular 
peroxiporin permeated H2O2 in cancer cells may result in 
downstream signalling events.  The exact nature of this association is 
currently widely investigated for its role in cancer cell regulation of 
proliferation, survival, differentiation, invasion and 
metastasis.58,77,81,86,132,149 
For example, AQP3 expression in tumour cells was correlated 
with NOX2 and epidermal growth factor receptor (EGFR) dependent 
cancer progression via hydrogen peroxide permeation. Knockdown 
of AQP3 reduced intracellular H2O2 concentrations, which impaired 
EGF-induced ERK and Akt activation and ultimately decreased 
tumour growth and migration.86 Another study focusing on breast 
cancer cells indicated a role for AQP3-mediated H2O2 uptake, 
produced by NOX2, in cell migration. The AQP3-transported H2O2 
activated the PI3K/Akt pathway by oxidizing PTEN (phosphatase and 
tensin homolog), showing overexpression of AQP3 promoted 
migration of breast cancer cells in association with elevated H2O2 
both in vitro as in vivo.58 AQP8-transported H2O2 produced by NOX 
upon vascular endothelial growth factor (VEGF) stimulation, seems 
to act in a similar way, by maintaining activation of Akt through 
oxidation of PTEN in leukaemia cell lines.77 Remarkably, AQP9 
downregulated expression was correlated with hepatocellular 
carcinoma cells migration. Over-expression of AQP9 resulted in 
decreased levels of PI3k/Akt and suppressed cell invasion in vitro and 
xenograft tumour growth in vivo.81  
These studies on the potential role of AQPs in H2O2 permeation 
in relation to cancer are relatively recent, and their possible 
importance as new therapeutic targets or biomarkers requires 
further investigation. This is illustrated by pharmacological 
ascorbate, a promising treatment in cancer therapy, that 
unfortunately shows a large variation in susceptibility.150,151 After 
intravenous administration, the ascorbate readily generates 
extracellular H2O2, which permeates the cancer cell membrane and 
 accumulate intracellularly, ultimately inducing cell death due to 
excessive ROS.152 The latest findings by Erudaitius et al. suggested 
that the success of pharmacological ascorbate treatment of 
pancreatic cancer may depend on peroxiporin (AQP3) expression.153 
Besides AQP3, AQP8 and AQP9, other isoforms are still explored as 
potential peroxiporins. AQP5, for example, is an interesting 
candidate due to its association with ERG and PTEN in prostate 
cancer,154 with EGFR/ERK in human glioma cell lines,91 and in 
hepatocellular carcinoma metastasis with NF-κB92. Interestingly, a 
recent study on rat AQP5 showed its ability to facilitate H2O2 
membrane diffusion in yeast.155 Thus, more research should be 
conducted to eluĐidate AQP5͛s possiďle ƌole as peƌoǆiporin in human 
cancers.   
3. Aquaporin Inhibitors 
As highlighted above, there is strong evidence for AQPs as drug 
targets in different diseases, including cancer. Moreover, analysis of 
the involvement of AQPs in the life cycle of disease-causing 
organisms (e.g. malaria parasites) suggests additional opportunities 
for pharmacological intervention in the treatment of human 
diseases. However, the identification of AQPs modulators (inhibitors) 
for both therapeutic and diagnostic applications has turned out to be 
extremely challenging.  So far, four classes of AQP-targeted small 
molecules have been described: (i) metal-based inhibitors; (ii) small-
molecules that are reported to inhibit water conductance (e.g., 
sulfonamides); (iii) small-molecules targeting the interaction 
between AQP4 and the neuromyelitis optica (NMO) autoantibody; 
and (iv) agents that act as chemical chaperones to facilitate the 
cellular processing of nephrogenic diabetes insipidus (NDI)-causing 
AQP2 mutants. 156 Despite numerous studies, for several of the small 
organic compounds to date no validation of their selectivity has been 
reported. Thus, in the following chapters, we will focus on the most 
promising metal-based AQPs inhibitors and their possible 
mechanisms of action described at a molecular level. 
3.1 AQPs inhibition by metal ions 
In normal physiology, AQPs can be regulated by various factors, 
including protein phosphorylation, pH and metal ions. The latter are 
mainly divalent cations, such as first-row transition metals, some of 
them being physiologically relevant. For example, Zelenina et al. 
have investigated the effects of Ni2+ (NiCl2) on the water permeability 
of AQP3 in human lung epithelial cells, showing that it is capable of 
decreasing permeability to only 30%, at a concentration of 1 mM 
after 1 min of incubation.157 The inhibition was shown to be 
reversible and Ni2+ did not have any effect on AQP4 or AQP5.  
Later, the same authors studied the effects of Ni2+ (as NiCl2) and Cu2+ 
(as CuSO4) on glycerol permeability and found that both ions reduce 
AQP3 permeability at a concentration of 1 mM in HEPES buffer. 158 
Interestingly, Pb2+ and Zn2+ ions had no effect on AQP3 permeability. 
Furthermore, AQP7, another aquaglyceroporin, was insensitive to 
copper. 
Zelenina et al. have also investigated which amino acid residues 
are involved in the inhibitory mechanism of both Ni2+ and Cu2+ ions 
by site-directed mutagenesis, and suggested serine, histidine and 
tryptophan residues as possible binding sites. 157,158 Interestingly, 
Ser152 was identified as a common determinant of both Ni2+/Cu2+ 
and pH sensitivity. All these residues are in the extracellular loops of 
the AQP3 monomers, and loop movement was observed in the 
͞gatiŶg͟ ŵeĐhaŶisŵ of seǀeƌal AQPs and appears to be a crucial 
feature in channel closure.159–161 For example, histidine residues in 
suĐh loops ĐaŶ ͚͚tuŶe͛͛ the pH seŶsitiǀitǇ of AQP3 towards certain pH 
values, as suggested by molecular modelling.162 
Among the benchmark AQPs inhibitors, the mercurial 
compounds pCMBS (p-chloromercurybenzene sulphonate) and HgCl2 
have been widely applied in in vitro biochemical assays to study AQPs 
function, despite their scarce selectivity and extreme toxicity. The 
mechanism of inhibition involves direct binding of Hg2+ ions to AQPs 
via modification of cysteine residues based on the classical hard soft 
acids and bases (HSAB) theory. In order to confirm such mechanism, 
several studies were performed on Cys-mutated isoforms of human 
AQP1. For example, Xenopus oocytes were transfected with Cys-
mutated AQP1 isoforms and the effects of mercury inhibition were 
evaluated.163 From all cysteine residues in AQP1, only one was shown 
to confer sensitivity to the mercurial salt HgCl2, namely Cys189. 
When this cysteine is mutated to either serine or glycine, water 
permeability of the oocytes was slightly decreased, indicating that 
this residue may be of importance for water transport. Moreover, 
cells expressing the Cys189Ser mutant lost sensitivity to HgCl2.  
The current literature provides two mechanisms of inhibition of 
AQPs by mercury: the first is simple occlusion of the water pore by 
the mercury ions found in the vicinity of the cysteine residues lining 
the pore; the second is conformational change (collapse of the water 
pore) at the selectivity filter (namely, the (ar/R) SF) region, induced 
by mercury bound to a cysteine residue nearby. 
The first hypothesis was formulated after the atomic-resolution 
structure of human AQP1 was solved, where Cys189 was shown to 
 be positioned inside the channel, just above the ar/R SF.27 Therefore, 
it was hypothesized that Hg2+ binding to this site was likely to prevent 
passage of water molecules via steric effects. 
The second mechanism of AQP inhibition by mercurial 
compounds was first proposed in an in silico study on the basis of 
molecular dynamics (MD) simulations of the bovine aquaporin AQP1 
(bAQP1).164 bAQP1 contains a cysteine residue (Cys191) in the ar/R 
SF region, which may bind Hg2+ similarly to hAQP1. According to the 
MD simulations of both free AQP1 and Hg-bound AQP1, the energy 
barrier for Hg-AQP1 is much higher than that of free AQP1 at the ar/R 
SF. Moreover, calculations show that mercury binding induces a 
collapse of the orientation of amino acid residues at the ar/R SF and 
the constriction of the space between Arg197 and His182. 
 Later on, our group investigated the molecular mechanism of 
inhibition of human AQP3 by Hg2+, using MD approaches.165 In 
support of the second mechanistic hypothesis, we observed 
important protein conformational changes upon binding of metal 
ions to Cys40 leading to a collapse of the ar/R SF, and subsequent 
blockage of water permeation.  
3.2 Gold complexes as inhibitors of aquaglyceroporins 
Recently, coordination gold(III) compounds have been identified as 
selective aquaglyceroporin inhibitors. In details, we have reported 
for the first time on the potent and selective inhibition of human 
AQP3 by the water-soluble gold(III) compound [Au(phen)Cl2]Cl (phen 
= 1,10-phenanthroline, Auphen, Fig. 6).166 Interestingly, Auphen 
inhibited glycerol transport in human red blood cells (hRBC), with an 
IC50 = 0.8  0.08 M, whilst having no inhibitory effect on water 
permeability mediated by the orthodox water channel AQP1.  
 
Fig. 6 Structure of the gold(III) complexes [Au(phen)Cl2]Cl (phen = 1,10-phenanthroline, 
Auphen) and [Au(1-methyl-2-(pyridin-2-yl)-benzimidazole)Cl2]PF6 (Au1), and 
[Au(bipy)Cl2]PF6 ;ďipǇ = Ϯ,Ϯ͛-bipyridine, Aubipy), inhibitors of human AQP3. 
 
In a further studǇ, ouƌ gƌoup eǆaŵiŶed AupheŶ͛s ĐapaĐitǇ of 
inhibiting cell proliferation in various cell lines with different levels of 
AQP3 expression.108 Our results showed a direct correlation between 
AQP3 expression levels and the inhibition of cell growth by the 
gold(III) compound. Functional studies also demonstrated AQP3 
inhibition in the cell lines where proliferation was affected by 
treatment with the gold compound. 
 Using molecular modelling approaches, we investigated the non-
covalent binding of Auphen to AQPs at a molecular level and found 
that its isoform selectivity is due to the accessibility to Cys40, whose 
thiol group is a likely candidate for direct binding to Au(III) 
complexes.166 The involvement of this residue in the inhibition 
mechanism was further confirmed by site-directed mutagenesis 
studies in a subsequent study.108 Additional results on other Au(III) 
compounds with different N^N ligand scaffolds allowed us to 
establish preliminary structure-activity relationships: the most 
effective compounds were those featuring at least one positive 
charge, one ligand that could be exchanged to allow metal 
coordination to protein residues, and aromatic ligands.167 
Unexpectedly, Au(I) complexes did not show any AQPs inhibition 
properties, implying that the hard-soft acid-base (HSAB) theory is not 
sufficient to predict the affinity for a metal compound for a certain 
protein binding site. Quantum mechanics/molecular mechanics 
(QM/MM) calculations suggested that the ligand moiety may play a 
major role in orienting the selectivity towards a certain isoform,167 
stabilizing the position of the inhibitor in the extracellular binding 
pocket.  
The reversibility of AQP3 inhibition was also studied by pre-
treating hRBC with the gold compounds for 30 min at r.t. and, 
subsequently, washing the cells with either excess of the thiol 
containing reducing agent -mercaptoethanol, the sulphur donor L-
Cys, or the N-donor His.167,168 In all cases, treatment with the 
competitor molecules led to an almost complete recovery of glycerol 
permeability, ruling out possible oxidative modification of amino acid 
residues by the Au(III) complexes.  
When the 1,10-phenantroline derivatives of Pt(II) and Cu(II) were 
also included in the investigation to compare the effects of metal 
substitution on the AQP3 inhibition potency, remarkably, the 
inhibition potency decreased drastically in the order: Auphen > 
Cuphen (IC50 = 81.9  4.1 M) >> Ptphen (IC50 > 200 M).167 
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 Recently, MD studies were conducted for the first time on 
another potent and selective inhibitor - the compound [Au(1-methyl-
2-(pyridin-2-yl)-benzimidazole)Cl2]PF6 (Au1, Fig. 6) - bound to Cys40 
of AQP3 (Fig. 7). 
 
Fig. 7 Representation of the mechanism of inhibition of AQP3 (white ribbon) by the 
gold(III) complex Au1 (dark teal ball and stick representation). Relevant amino acids are 
shown in grey stick representation, with the backbone and hydrogens hidden for clarity. 
Interactions are shown in dashed lines: cyan for H-bonds and green for arene-H.  
 
The obtained results showed that protein conformational changes 
upon metal binding to Cys40, and not direct steric blockage of the 
channel by the metal compound, are mostly responsible for the 
observed inhibition of water and glycerol permeation (Fig. 8).168 
These findings are in line with the above-mentioned studies on AQPs 
inhibition by mercury. Furthermore, binding of Au1 in one monomer 
also affects substrate permeability in an adjacent one, thus, altering 
the overall extracellular distribution of hydrophobic/hydrophilic 
surfaces of the tetramer, which, in turn, orients the approach of the 
substrates to the pore. Moreover, in this study, a correlation 
between the affinity of the Au(III) complex towards Cys binding and 
AQP3 inhibition was highlighted, while no influence of the different 
oxidative character of the metal complexes was observed.168 
 Further investigation of another selective AQP3 inhibitor, the 
gold(III) cationic complex [Au(bipy)Cl2]PF6 (bipy = Ϯ,Ϯ͛-bipyridine, 
Aubipy,  Fig. 6), bound to the protein channel, has been performed 
by means of a multi-level theoretical workflow that includes QM, MD 
and QM/MM approaches.169 In this study, three key aspects for AQP3 
inhibition by gold compounds have emerged: i) speciation of the 
gold(III) complex prior protein binding (formation of aquo-
complexes), ii) stability of non-covalent adducts between the 
compound aromatic ligand and the extracellular pore side, and iii) 
conformational changes induced within the pore by the coordinative 
binding of Au(III) ions leading to pore closure, in line with the above-
mentioned study on Auphen.  
Fig. 8 (A) Human AQP3 monomer A and (B) AQP3 with Cys40 bound to the Au(III) 
complex Au1, showing the effect on pore size (based on VDW radii): red = smaller than 
single H2O, green = single H2O, blue = larger than single H2O. Complex Au1 and Cys40 are 
shown in ball and stick representation, with atoms coloured by atom type. Reproduced 
by permission of The Royal Society of Chemistry from 168. 
 
Notably, in this latter study, we suggest that the presence of thiol 
binding sites in AQP3 is necessary but not sufficient to determine the 
selectivity of Aubipy.169 Instead, the formation of stable non-
covalent Aubipy-AQP3 adducts is required to compensate the 
thermodynamic and kinetic barriers associated with the formation of 
the final covalent Au-Cys adduct. In detail, the overall Aubipy-AQP3 
binding process may be described as depicted in Fig. 9. 
 
 
Fig. 9 Proposed mechanism of interaction of the Au(III) complex Aubipy with AQP3. 
 
Overall, these results have important implications for future 
iŶhiďitoƌs͛ desigŶ, showing that amino acid residues other than those 
lining the pore could be targeted, provided that their modification 
leads to the necessary conformational changes to achieve channel 
closure. In addition, careful fine-tuning of the interactions between 
the metal complex and specific residues at the pore extracellular 
entrance, leading to the formation of the first non-covalent adduct, 
may be achieved by different substituents on the ligand bound to 
Au(III), as well as by the use of different aromatic scaffolds (e.g., C^N-
cyclometallated and benzimidazole ligands). In this way, one may 
increase the selectivity of the compound for inhibition of AQP3 
compared with other aquaglyceroporin isoforms.  
Selectivity of aquaglyceroporin inhibition is essential to deliver a 
targeted therapy, dependent on the isoform of interest. In fact, 
Auphen was also observed to inhibit AQP7 although with lower 
 
 potency and different mechanism of inhibition, as indicated by 
permeability studies and molecular modelling approaches, 
respectively.170 Specifically, whilst Cys residues corresponding to 
Cys40 in AQP3 are not available, several Met side chains are 
accessible, either on the extracellular or the intracellular side of 
human AQP7, for binding to Au(III) complexes. 
The fact that the inhibition mechanism of the same compound 
with two different AQPs may be different, indicates that it is possible 
to take advantage of even small structural differences between the 
isoforms to optimize the inhibitor͛s ĐheŵiĐal sĐaffold aŶd, thus, to 
achieve selectivity.  
4. Conclusions and Perspectives 
Clinical and preclinical studies evidence that AQP expression is 
increased in a number of cancers. Therefore, in recent years, 
biological functions and signalling pathways of AQPs in cancer have 
been intensively investigated in a condition of AQP depletion, using 
genetic approaches. AQPs are also involved in the carcinogenesis and 
pathogenesis of tumour-associated oedema, tumour cell 
proliferation and migration. The exact nature of this correlation is 
still the subject of discussion, emphasizing the need to develop 
targeted modulators to study the mechanism of these potential 
therapeutic targets. In fact, numerous in vivo and in vitro studies 
have shown several attractive opportunities for AQP-targeted 
therapy. Furthermore, some of the aquaglyceroporins have also 
been postulated to be responsible for the uptake of inorganic 
chemotherapeutics, such as the anti-leukemic arsenic trioxide.7 
Within this framework, the possible contribution of bio-inorganic 
chemistry is crucial, in that, taking advantage of the promising 
studies on gold(III) compounds as selective aquaglyceroporins 
inhibitors, and in combining highly integrated investigational 
approaches, new metal-based complexes may be optimized to target 
specific AQPs isoforms. For example, we consider copper complexes 
as alternative promising candidates to gold compounds, and ongoing 
studies in our lab aim at designing new ligand systems able to favour 
the binding of Cu(II) and Cu(I) ions to AQPs. Thus, the design and use 
of either coordination or organometallic metal compounds may 
unravel unexpected roles of AQPs in the molecular mechanisms of 
diseases and provide new tools in chemotherapy and imaging.  
Finally, inorganic chemistry offers important advantages with 
respect to organic chemistry. For example, metal complexes 
constitute an ideal drug design platform, where not only the 
geometric properties of the molecule can be easily varied, but also 
offeƌiŶg the possiďilitǇ of ͞fine-tuŶiŶg͟ the ƌeaĐtiǀitǇ of the 
compounds via appropriate ligaŶds͛ ĐhoiĐe, ŵaiŶtaiŶiŶg the AQPs 
inhibition activity while reducing the side-effects. 
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